The p53/MDM2/MDMX-targeted therapies – a clinical synopsis
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The cost of cancer care accelerates because of the growing number of cancer patients and the increasing expenses of drug innovations. The approval of costly second-line therapies like immune checkpoint inhibitors or CAR-T therapies contributes to this trend. Hence, drug repurposing, which uses drugs originally approved for other indications, is emerging as a necessary approach in cancer care, due to its comparatively low innovation and treatment costs and predictable side-effects 1 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“development of an acetylation targeting chimera (AceTAC) targeting p53 acetylation has shown promising results, while other attempts to target the p53-Mdm2 interaction thus far have struggled [39–41].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [39]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401753e · Cited by 290
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Carvajal, L. A., Neriah, D. B., Senecal, A., Benard, L., Thiruthuvanathan, V., Yatsenko, T., Narayanagari, S.-R., Wheat, J. C., Todorova, T. I., Mitchell, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao3003 · Cited by 249
p53 as a hub in cellular redox regulation and therapeutic target in cancer
Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz005 · Cited by 123
Reis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., Dickinson, M. J., Drummond, M., Assouline, S., Hashemyan, M., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139717 · Cited by 91
Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
Skalniak, L., Kocik, J., Polak, J., Skalniak, A., Rak, M., Wolnicka-Glubisz, A., & Holak, T. (2018) · Cancers · doi:10.3390/cancers10110396 · Cited by 73
Cited by
The roles and regulation of MDM2 and MDMX: it is not just about p53
Klein, A. M., de Queiroz, R. M., Venkatesh, D., & Prives, C. (2021) · Genes & Development · doi:10.1101/gad.347872.120 · Cited by 129
Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies
Molinaro, C., Martoriati, A., & Cailliau, K. (2021) · Cancers · doi:10.3390/cancers13153819 · Cited by 104
Lv, L., Fan, B., Ji, X., Liu, Y., Chen, T., Li, Y., Gao, X., Chen, P., Tang, B., & Chen, G. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215733 · Cited by 76
Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
Zhang, S., Carlsen, L., Hernandez Borrero, L., Seyhan, A. A., Tian, X., & El-Deiry, W. S. (2022) · Biomolecules · doi:10.3390/biom12040548 · Cited by 70
Mafi, A., Rahmati, A., Babaei Aghdam, Z., Salami, R., Salami, M., Vakili, O., & Aghadavod, E. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00354-4 · Cited by 56
Metadata
- Authors
- Jiang, L., & Zawacka-Pankau, J.
- Affiliations
- Shanghai Jiao Tong University (CN)
- ORCID
- Jiang, Liren
- Venue
- Cell Death & Disease
- Published
- 2020-04-17
- Volume
- 11
- Issue
- 4
- Pages
- 237-237
- ISSN
- 2041-4889 (ISSN-L)
- PMC
- PMC7165174
- OpenAlex
- W3016812120
- Cited by
- 62
- References
- 19
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 11 · 2023: 9 · 2022: 15 · 2021: 12 · 2020: 7
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death and Disease (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, MDM2, MDMX, targeted cancer therapy, drug repurposing, cancer treatment costs, immune checkpoint inhibitors, CAR T-cell therapy
- MeSH terms
- Humans, Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The p53/MDM2/MDMX-targeted therapies – a clinical synopsis. https://app.cochat.ai/papers/10.1038/s41419-020-2445-9
- The paper
- Jiang, L., & Zawacka-Pankau, J. (2020). The p53/MDM2/MDMX-targeted therapies – a clinical synopsis. Cell Death & Disease. https://doi.org/10.1038/s41419-020-2445-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.